Clinical Trials Logo

Clinical Trial Summary

Based on evidence that radiation-induced damage to the hippocampus plays a considerable role in neurocognitive decline after cranial irradiation, hippocampal-sparing whole brain radiation therapy (HS-WBRT) has been proposed. This study will investigate the neurocognitive function and prognosis between HS-WBRT and conventional WBRT for the treatment of brain metastases from breast cancer.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT03002532
Study type Interventional
Source Affiliated Hospital to Academy of Military Medical Sciences
Contact Zheng Jiang
Phone 861066947017
Email [email protected]
Status Recruiting
Phase N/A
Start date August 2015
Completion date August 2017

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04474925 - Pre- Versus Post-operative SRS for Resectable Brain Metastases Phase 3
Not yet recruiting NCT03613181 - ANG1005 in Leptomeningeal Disease From Breast Cancer Phase 3
Not yet recruiting NCT04955743 - Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Phase 2
Not yet recruiting NCT04689048 - Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery Phase 1
Completed NCT02082587 - Toronto BNB Pilot Study N/A
Terminated NCT01551680 - A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases Phase 1
Terminated NCT00717275 - Study of Temozolomide to Treat Newly Diagnosed Brain Metastases Phase 2
Recruiting NCT03714243 - Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases N/A
Not yet recruiting NCT04856475 - Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer Phase 2
Recruiting NCT04170777 - Perfexion Registration Using CBCT
Not yet recruiting NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04582968 - Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT03027544 - Tomotherapy for Refractory Brain Metastases N/A
Completed NCT04178330 - Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases N/A
Terminated NCT02187822 - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Phase 1
Recruiting NCT04246879 - MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases N/A
Active, not recruiting NCT03653546 - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases Phase 2/Phase 3
Recruiting NCT04410133 - Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases Phase 3
Recruiting NCT04040400 - Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resection N/A
Recruiting NCT04824079 - Keynatinib in Treated Patients With NSCLC and Brain Metastases Phase 2